Our Core Technologies result from years of both private and university research and development by pioneers in the field of biotechnology, in collaboration with medical practitioners within various fields of medicine throughout the world.

PERIPHERAL BLOOD DERIVED PLURIPOTENT STEM CELLS

“nPSC TECHNOLOGY”

Our nPSC Technology is based on discoveries involving a distinct population of pluripotent stem cells, initially isolated from adipose-tissue, but found in abundance in bone marrow, from where they originate, and present in peripheral blood, as well as other body fluids. These cells express a unique marker that can be used to select them for both diagnostic and therapeutic procedures utilizing a proprietary antibody on its own or in combination with existing commercially available antibodies. These cells are in abundance in peripheral blood and in reproductive tissue secretions and dissipate in number and function in humans as they age. The Company’s scientists have determined that these cells play a large role in future stem cell based diagnostic and therapeutic applications in both humans and animals. Furthermore, unlike adipose tissue derived cells, peripheral blood derived pluripotent stem cells can be taken from healthy donors.

The nPSC Technology relies upon a proprietary antibody manufactured for the unique detection and isolation of Peripheral Blood Derived Parathyroid Hormone Receptor Positive Pluripotent Stem Cell. The Company has developed two processes for detection and isolation of these cells.

Patent’s regarding the various applications of the nPSC Technology have been filed, and the proprietary antibody, necessary for the positive selection of the parathyroid hormone receptor positive peripheral blood derived pluripotent stem cells is a unique component protected as a trade secret.

Potential Use

Current research has shown that  the nPSC Technology is suitable for cell banking and for future use in both regenerative therapies and tissue engineering.